| Today’s Big NewsApr 29, 2024 |
|
Therapeutic RNAs offer several advantages over other therapies due to their specificity and versatility, leading researchers to make great strides towards personalized medicine. Download the QPS white paper for insights into the future of RNA Therapies. 
|
|
| By James Waldron Japan’s Ono Pharmaceutical is picking up Deciphera Pharmaceuticals for $2.4 billion, a price tag that brings both the approved cancer drug Qinlock and another candidate heading to the FDA’s desk in the coming months. |
|
|
|
By Conor Hale At its heart, the 528-page final rule looks to make clear that in vitro diagnostic tests are to be considered medical devices like any other. |
By Annalee Armstrong Annovis Bio heralded a “significantly higher rate of improvement” in patients with Alzheimer’s disease who received buntanetap, however digging a little deeper into the muddled readout suggests the trail was a failure. |
By Nick Paul Taylor Pharma’s pandemic-era halo is slipping. After tracking a surge in the industry’s reputation, PatientView found patient groups soured on drugmakers somewhat last year to send pharma’s standing to its lowest level since 2020. |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
By Conor Hale Abbott has returned to the field of bio-absorbable, dissolving stents, and in somewhat uncharted territory. The Esprit BTK implant aims to treat the most severe form of peripheral artery disease, a condition known as chronic limb-threatening ischemia. |
By Angus Liu AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself. After spearheading the new HER2-low category in breast cancer treatment, Enhertu has shown it could be useful against tumors with even lower expression of the HER2 protein. |
By Annalee Armstrong The U.S. FDA is planning to hold an advisory committee meeting on…well, advisory committee meetings. |
By Andrea Park Just a few months after announcing their team-up, Merck KGaA and Huma Therapeutics have already checked off the first item on their joint to-do list. |
By Kevin Dunleavy Five months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar 20. Now, the company is comparing the investigational shot to its old warhorse, Pneumovax 23 (PPSV23). |
By Conor Hale The FDA has bestowed a green light to a companion diagnostic for Pfizer’s recently approved hemophilia B gene therapy—because at a cost of $3.5 million per dose, you want to make sure it will work. |
By Zoey Becker After last quarter presenting three factors necessary for a more successful launch of hemophilia A gene therapy Roctavian, BioMarin has now added a divestiture to the list of potential paths for the struggling medicine. |
By Nick Paul Taylor Regeneron and Sanofi are back with another push to show how Dupixent can help people with asthma “Du More.” The fourth generation of the campaign dials up the humor to try to connect with patients on the No. 1 driver of visits to the doctor: breathing. |
By Nick Paul Taylor Bristol Myers Squibb is placing a $65 million bet on Repertoire Immune Medicines’ approach to resetting the immune system. The deal, which features up to $1.8 billion in future payments, gives BMS the right to collaborate with Repertoire on tolerizing vaccines for up to three autoimmune diseases. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now. 
|
|
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
